Table 4.

Tumor characteristics associated with statin use

Tumor characteristicStatin use, ≥2 yStatin use, neverOR* (95% CI)
ER status
    ER+1,623 (10.6)13,730 (89.4)Reference
    ER−265 (7.33)3,349 (92.7)0.88 (0.76-1.02)
PR status
    PR+1,307 (10.5)11,181 (89.5)Reference
    PR−571 (8.9)5,840 (91.1)0.89 (0.80-0.99)
HER2 status
    HER2−1,059 (17.3)5,075 (82.7)Reference
    HER2+250 (13.6)1,585 (86.4)0.90 (0.77-1.06)
Intrinsic subtype
    Luminal A948 (18.2)4,265 (81.8)Reference
    Luminal B178 (13.8)1,110 (86.2)0.94 (0.85-1.04)
    HER2+/ER−71 (13.0)474 (87.0)0.93 (0.79-1.07)
    Triple negative111 (12.1)810 (87.9)0.90 (0.78-1.01)
Tumor stage
    Localized1,325 (10.7)11,011 (89.3)Reference
    Regional493 (8.3)5,422 (91.7)0.99 (0.93-1.05)
    Metastasis60 (10.3)520 (89.7)1.05 (0.90-1.20)
Tumor grade
    Grade I460 (11.6)3,492 (88.4)Reference
    Grade II783 (10.7)6,544 (89.3)1.02 (0.96-1.09)
    Grade III397 (7.8)4,714 (92.2)0.97 (0.90-1.05)
  • *Adjusted for age, coverage, oral contraceptive use, hormone therapy use, and race.

  • P < 0.05.

  • HER2 status was only evaluated in tumors from 2002 to 2007.